Instituição onde foi realizado o trabalho
- Principal: CENOFT- Centro Oftálmico Tarcízio Dias
- HETHMA NOBREGA QUINHO CARVALHO (Interesse Comercial: NÃO)
- JUAN CARLOS LUNA DA COSTA (Interesse Comercial: NÃO)
- NILTON DA SILVA ALVES FILHO (Interesse Comercial: NÃO)
USE OF INTRAVITREAL INJECTIONS OF BEVACIZUMAB AND CHANGES IN IRIDOCORNEAL ANGLE PARAMETERS
The primary objective was to measure the changes in iridocorneal angle in the immediate post injection period using anterior segment optical coherence tomography (AS-OCT). Secondary objectives were to determine if those changes are associated with age, sex and the presence of pseudophakia.
Eyes were enrolled into two groups: bevacizumab and control. The following AS-OCT parameters were measured: trabecular-iris angle (TIA), angle opening distance (AOD 500, AOD 750) and trabecular-iris space area (TISA 500, TISA 750) before and after injection.
The mean age ± SD was 60.5 ± 13.9 years, range was 25–83 years. Ten individuals were male and 22 were female. Sixty-four eyes were included. We verified a statistically significant reduction in all parameters between pre and post injection in bevacizumab group: pre TIA/post TIA = 34.859 /32.918 mm (95% CI – 24.850 to 44.868/23.053 to 42.780; P=.026), pre AOD500/post AOD500 = 0.614/0.552 mm (95% CI – 0.363 to 0.865/0.320 to 0.784; P<.001), pre AOD750/post AOD750 = 0.835/0.754 mm (95% CI – 0.363 to 1.19/0.431 to 1.77; P<.001), pre TISA500/post TISA500 = 0.218/0.196 mm 2 (95% CI – 0.128 to 0.308/0.104 to 0.288; P=.003), pre TISA750/post TISA750 = 0.399/0.360 mm 2 (95% CI – 0.235 to 0.563/0.210 to 0.510; P<.001).
A narrowing of the iridocorneal angle assessed with AS-OCT was confirmed after a single injection of bevacizumab. Physicians performing such injections should be aware of these changes as they may increase risk of angle closure, especially in cases of narrow angles.